Crossmark

Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Crossref DOI link: https://doi.org/10.1186/s13045-019-0727-4

Published Online: 2019-04-25

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Saraceni, Francesco https://orcid.org/0000-0001-6500-9514
Labopin, Myriam

Brecht, Arne

Kröger, Nicolaus

Eder, Matthias

Tischer, Johanna

Labussière-Wallet, Hélène

Einsele, Hermann

Beelen, Dietrich

Bunjes, Donald

Niederwieser, Dietger

Bochtler, Tilmann

Savani, Bipin N.

Mohty, Mohamad

Nagler, Arnon
License Information

Text and Data Mining valid from 2019-04-25
More Information

Article History

Received: 5 January 2019

Accepted: 31 March 2019

First Online: 25 April 2019

Ethics approval and consent to participate

: Since 1990, patients provide informed consent authorizing the use of their personal information for research purposes.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below